The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study

Completed

• Conditions: Esophageal Cancer
• Interventions: Diagnostic Test: Since the data were collected retrospectively, there were no interventions

• Registration Number: NCT05617352
• Lead Sponsor: Yongtao Han

Brief Summary

To clarify the effect of Two-field or Three-field Lymphadenectomy on the survival of esophageal squamous cell carcinoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-01
• Primary Completion: 2022-10-01
• Study Completion: 2022-10-10
• Status Verified: 2022-11
• Study First Submitted: 2022-11-07
• Study First Submitted QC: 2022-11-07
• Study First Posted: 2022-11-15
• Last Update Submitted: 2022-11-18
• Last Update Posted: 2022-11-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1659

Inclusion Criteria

• 1. Men and women aged 18-85 years
• 2. Histologically confirmed primary thoracic esophageal squamous cell carcinoma,
• 3. Staging PT1b-4A, N0-3, M0 AJCC eighth edition
• 4. Excluding lymph node dissection < 15, (meeting the guideline criteria)
• 5. The tumor located in the lower middle thoracic.

Exclusion Criteria

• 1. Patients with a history of previous thoracic and abdominal surgery that may affect lymphatic reflux
• 2. Patients with distant metastasis confirmed by imaging
• 3. Patients with obvious surgical contraindications.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
3F Group	Since the data were collected retrospectively, there were no interventions	Patients with Three-field Lymphadenectomy
2F Group	Since the data were collected retrospectively, there were no interventions	Patients with Two-field Lymphadenectomy

Primary Outcome Measures

Name	Time	Method
The number of lymph nodes	2010.1.1-2017.12.30	Surgical data were retrospectively collected

Trial Locations

Locations (1)

Sichuan Cancer Hospital; 🇨🇳 Chendu, Sichuan, China